Short communicationLC–MS/MS quantitation of ribavirin in serum and identification of endogenous isobaric interferences
Review articleOpen access
2011/11/20 Short communication DOI: 10.1016/j.cca.2011.07.016
Journal: Clinica Chimica Acta
AbstractBackgroundRibavirin is a nucleoside analog used in treatment of chronic hepatitis C. It is associated with severe, dose-dependent toxicities, including hemolytic anemia. To facilitate therapeutic drug monitoring, a liquid chromatography–tandem mass spectrometry method was validated for quantitation of ribavirin in serum.MethodsAfter protein precipitation, ribavirin is quantitated using a 13C5-ribavirin internal standard, on a Hypercarb analytical column designed for retention of polar analytes.ResultsThe analytical method shows excellent precision, sensitivity, and specificity. In vitro drug stability was also assessed. Interestingly, endogenous isobaric compounds were noted in both human and bovine serum; these could be chromatographically separated from the ribavirin peak. Addition of exogenous uridine and cytosine increases the size of the isobaric peaks, suggesting that these compounds are the source of the endogenous interference.ConclusionsThis method uses mass spectrometric transitions that have been used in other published methods, but also separates ribavirin from isobaric peaks that were not described. These peaks were determined to be endogenous nucleosides. Laboratories quantitating ribavirin in biological matrices should be aware of the potential for isobaric interferences, and take steps to chromatographically separate them from the ribavirin peak for accurate quantitation.
Request full text